The common patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant I148M predisposes to non-alcoholic liver disease but not its metabolic sequelae.
INTRODUCTION
The I148M variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is found worldwide in 30-50% of all subjects (1) . It increases intrahepatocellular triglycerides (IHTGs) and risks of non-alcoholic steatohepatitis (NASH), alcoholic and non-alcoholic cirrhosis and hepatocellular carcinoma (2) .
Unlike in non-alcoholic fatty liver disease (NAFLD) associated with obesity and metabolic syndrome, carriers with NAFLD due to the I148M gene variant are neither insulin resistant nor predisposed to develop metabolic sequelae such as cardiovascular disease compared to non-carriers (1) . Indeed, several studies have recently shown the gene variant to be protective against cardiovascular disease (3, 4) .
In humans, hepatic TGs are markedly enriched in polyunsaturated fatty acids (PUFA) in carriers of the PNPLA3 I148M variant compared to non-carriers (5) . This lipidome differs from the NAFLD lipidome associated with insulin resistance, in which liver is enriched in predominantly saturated or monounsaturated TGs (5) . The human lipidomic data of NAFLD in PNPLA3 variant carriers closely resemble the hepatic lipidomic profile of PNPLA3 knock-out (ko) mice (6, 7) . In the latter study, PNPLA3 was proposed to act as a transacylase transferring PUFAs from TG to lyso-phospholipids or as a TG hydrolase hydrolyzing PUFAs from TGs in a remodeling pathway for lipid droplet phospholipids (7) . However, data from mouse models are not easy to reconcile with the human data.
PNPLA3-ko mice accumulate polyunsaturated TGs but do not develop hepatic steatosis (6) (7) (8) . Opposite to humans and knock-in mice expressing a catalytically inactive PNPLA3 (PNPLA3-S47A-ki), PUFAs are depleted in hepatic TGs in I148M knock-in mice, i.e. in mice in which the I148M has been introduced to the endogenous mouse PNPLA3 gene (7) . Mouse PNPLA3 is approximately 68% homologous with human PNPLA3 (9) . This difference could contribute to the discrepant results in mice as compared to humans. Regarding cell models, hepatic cell lines such as HuH7 and HepG2 are not ideal for studying the function of the PNPLA3 I148M variant as both cell lines are homozygous for the variant allele (10, 11) . There are no studies addressing the function of the PNPLA3 I148M variant in humans in vivo or in vitro in human cells that do not endogenously express the I148M variant and in which the variant has been knocked-in rather than overexpressed.
In the present study, we wished to determine why PUFAs are enriched in TGs in the human liver. This is important for understanding the pathogenesis of the most important genetic risk factor of NAFLD. To this end, we compared the hepatic handling of labeled PUFAs ( 13 C-18:2) and saturated fatty acids (SFAs, 13 C-16:0) and the composition of VLDL in homozygous carriers and non-carriers of the PNPLA3 I148M variant. Furthermore, by using CRISPR-Cas9 we engineered human cells homozygous for the PNPLA3 148I allele (PNPLA3-148I, wt) to generate cell lines with a homozygous I148M substitution (PNPLA3-148M-ki) or a homozygous PNPLA3 deletion (PNPLA3-ko). In these cells we employed "click" chemistry of alkyne-labeled C-18:2 and C-16:0 FAs to analyze rapid fatty acid fluxes during lipogenesis and lipolysis.
Finally, we compared the lipid composition of human liver biopsies between homozygous carriers and non-carriers of the I148M variant.
RESULTS

Increased IHTGs in homozygous 148M variant allele carriers (PNPLA3 148MM ) compared to non-carriers (PNPLA3 148II )
Characteristics of the PNPLA3 148II and PNPLA3 148MM groups are shown in Table 1 .
The PNPLA3 148MM group had a significantly and 3.5-fold higher IHTG content than the PNPLA3 148II group (6.3 [4.5 -14.6] vs. 1.8 [1.0 -6.7] %) ( Table 1 ). The PNPLA3 148II and PNPLA3 148MM groups were similar with respect to age, gender, glucose and insulin concentrations and BMI ( Table 1 ). There were no significant differences between the groups in physical activity or dietary intake as determined by 1-week accelerometer data and analysis of 3-day dietary records ( Table S1 ).
Deficiency of polyunsaturated TGs in VLDL in the PNPLA3 148MM as compared to the PNPLA3 148II group
Total concentrations of plasma TG, free fatty acids (FFA), VLDL-TG and chylomicron-TG and glucose and serum insulin concentrations were similar between the PNPLA3 148MM and PNPLA3 148II groups in the fasting state and postprandially at every time point (Figure 1 ). Lipidomic analysis of VLDL was performed for detailed characterization of VLDL-TGs in the fasting state and postprandially. The relationship between the number of double bonds in VLDL-TGs and the ratio of the mean absolute concentrations of corresponding VLDL-TGs in the PNPLA3 148MM as compared to the PNPLA3 148II group are shown in Figure 2 . The number of double bonds was inversely related to the ratios of VLDL-TGs in PNPLA3 148MM vs. PNPLA3 148II in the fasting state and at 120 min, 300 min and 420 min postprandially (Figure 2) . Thus, although total concentrations of VLDL-TGs were similar (Figure 1) , the TGs secreted from the liver in VLDL before and during the meal were deficient in polyunsaturated TGs in the PNPLA3 148MM as compared to the PNPLA3 148II group.
Deficiency of PUFA in VLDL-TG fatty acids in the PNPLA3 148MM as compared to the PNPLA3 148II group
The percentage of distinct fatty acids of total fatty acids in VLDL-TGs in the PNPLA3 148MM as compared to the PNPLA3 148II group in the fasting state are shown in The relationship between the number of double bonds in VLDL-TG fatty acids and the ratio of the mean absolute concentrations of corresponding VLDL-TG fatty acids in the PNPLA3 148MM as compared to the PNPLA3 148II group are shown in Figure 3E . The number of double bonds was inversely related to the ratios of VLDL-TG fatty acids in homozygous carriers vs. non-carriers during the postprandial period ( Figure 3E) . These data show that there is polyunsaturated fatty acid deficiency in VLDL-TG in 148M carriers and support the hypothesis that PUFAs are retained in the liver in PNPLA3 148MM as compared to the PNPLA3 148II group.
In vivo evidence of retention of labeled 13 C-18:2 PUFA in the human liver in PNPLA3 148MM compared to PNPLA3 148II group Dietary fatty acids are transported from the intestinal lumen to the circulation in chylomicron-TGs, which then undergo hydrolysis and are taken up by the liver (12) .
VLDL-TGs are produced exclusively by the liver (12) . Thus, to compare handling of PUFAs and SFAs in the liver, we calculated their ratio in VLDL-TGs and chylomicron-TGs. The PNPLA3 148MM group had a significantly lower 13 C-18:2/ 13 C-16:0 ratio in VLDL-TGs compared to the PNPLA3 148II group (p<0.01) when related to the corresponding ratio in the chylomicron precursor pool ( Figure 3F ). There were no differences in enrichment of either of the fatty acids in the chylomicron precursor pools between the PNPLA3 148MM and the PNPLA3 148II (data not shown).
Increased storage of neutral lipids in homozygous PNPLA3 148M-ki human cells
We used human epidermoid carcinoma A431 cells that are readily amenable for genetic manipulation and homozygous for the PNPLA3-148I allele. PNPLA3 is expressed in the skin (13) and in A431 cells at levels roughly comparable to HepG2 cells (Human Protein Atlas). We have used these cells in our earlier studies on lipid processing and storage (14, 15) . Starting from the wt PNPLA3 cells, we engineered PNPLA3-ko cells as well as cells expressing the 148M allele as homozygous (PNPLA3-148M-ki) and N=6). We also engineered cells stably expressing GFP-tagged PNPLA3-148I or PNPLA3-148M on a PNPLA3-ko background. In these cells, both forms of PNPLA3 are expressed at similar levels ( Figure S2A ) and associate with lipid droplets ( Figure   S2B ). These results are in keeping with our previous findings in hepatoma cells (16) .
Increased storage of PUFAs but not SFAs in PNPLA3 148M-ki and PNPLA3-ko cells
We then studied how addition of saturated or increasingly unsaturated exogenous fatty acids affects lipid storage in A431 cells. Fluorescence microscopy revealed that all three cell lines generated lipid droplets when exposed to fatty acids for 24 h. Expectedly, oleic and palmitic acid were potent inducers of lipid droplets, and PUFAs were less efficient (Figure 4 ). However, lipid droplet accumulation induced by PUFAs was strikingly increased in PNPLA3-148M-ki and PNPLA3-ko cells. This effect was not observed with saturated or monounsaturated FA. These results show that lack of PNPLA3 activity results in preferential sequestering of PUFAs to neutral lipids.
Increased incorporation of PUFAs to TGs and decreased incorporation to PCs in
PNPLA3-148M-ki and PNPLA3-ko cells
Click chemistry is powerful for tracing rapid fatty acid metabolism (15, 17) . Using this approach, we compared how alkyne-palmitate and alkyne-linoleate are metabolized 
Accumulation of DAGs in PNPLA3-148M-ki and PNPLA3-ko cells in lipolytic conditions
Due to the observed differences between PNPLA3 genotypes in PUFA metabolism and the reported PNPLA3 lipase activity (18, 19) , we next measured release of linoleic acid from TG stores. To this end, we incubated wt A431 cells with alkyne-linoleate for 1 h in the presence of a cholesterol esterification inhibitor (PKF-035; to ensure maximal neutral lipid deposition as TGs). The cells were then either immediately harvested (0 min chase) or incubated for 15, 30 or 60 min (chase) in the presence of diacylglycerol O-acyltransferase (DGAT) 1 and 2 inhibitors that prevent TG synthesis as well as a cholesterol esterification inhibitor. As the inhibitors prevent fatty acid re-esterification to neutral lipids, under these conditions, cells start to hydrolyze the generated TGs. As expected, alkyne-linoleate containing TGs and DAGs decreased during chase and this was paralleled by increased partitioning of alkyne-linoleate into phospholipids, with marginal levels of FFAs (Figure S3A) .
When the effect of PNPLA3 genotype on TG hydrolysis was investigated, we found that both PNPLA3-148M-ki and PNPLA3-ko cells had elevated TG levels at the end of alkyne-linoleate labeling as compared to PNPLA3-148I ( Figure 5C ). The increase in TGs in PNPLA3-ko and 148M-ki cells is consistent with the idea that the human gene variant increases TGs because it acts as a loss-of function variant. During the 1 h chase, TGs started to diminish but stayed elevated in both genotypes relative to PNPLA3-148I cells (Figure 5C ). Of note, although TGs stayed elevated in PNPLA3-ko and 148M-ki cells compared to wt PNPLA3-148I cells, we did not observe major differences in the hydrolysis rate of TGs under lipolytic conditions between these cells. This does not favor the idea that PNPLA3 functions mainly in TG hydrolysis.
Strikingly, under lipolytic conditions we observed a pronounced increase in DAGs in both PNPLA3-148M-ki and PNPLA3-ko cells as compared to wt (Figure 5C ). This effect was not observed during the 15 min labeling (Figure 5B ), suggesting that the increase was not due to increased generation of DAGs but rather to their impaired hydrolysis. In PNPLA3-148M-ki and PNPLA3-ko cells, there was also a tendency for decreased incorporation of alkyne-linoleate into PCs, but the difference was not significant (Figure S3B ). This is not surprising, because during the course of hour(s) linoleic acid can end up in the PC pool via several pathways.
Polyunsaturated TGs are enriched while PCs are deficient in the human liver in homozygous carriers of the PNPLA3 I148M variant compared to non-carriers
Since polyunsaturated TGs accumulated in the PNPLA3-148 cells at the expense of PCs, we next asked whether the enrichment of polyunsaturated TGs would be associated with a decrease in PCs in the human liver in homozygous carriers of the PNPLA3 I148M variant as compared to non-carriers. To this end, we re-analyzed previously described data of human liver lipidome (5) To explore the mechanism explaining retention of PUFAs in the human liver, we engineered PNPLA3-ko cells as well as cells expressing the 148M allele as homozygous (PNPLA3-148M-ki) and generated stable cell lines. This knock-in model of the PNPLA3 variant is the first to examine the impact of endogenous levels of the human PNPLA3 variant on lipid composition and metabolism. In previous studies using human cell lines (16, 20, 21) the gene variant was overexpressed, potentially causing artefacts.
Lipid droplet accumulation induced by PUFAs but not by saturated or monounsaturated FA was strikingly increased in PNPLA3-148M-ki and PNPLA3-ko cells. These results suggest that lack of PNPLA3 activity results in preferential sequestering of PUFAs to neutral lipids and that the 148M variant resembles loss of PNPLA3 function in human cells.
Studies using click chemistry allow tracing of rapid changes in fatty acid metabolism (17) . In PNPLA3-148M-ki and PNPLA3-ko cells, the fraction of alkyne-linoleate in PC was significantly reduced and in TGs increased as compared to wt cells. In human liver samples, concentrations of polyunsaturated PCs were significantly decreased while TGs were increased in the livers of homozygous carriers of the PNPLA3 I148M variant as compared to non-carriers (Figure 6) . These data closely resemble those of knock-in mice expressing a catalytically inactive PNPLA3 variant (PNPLA3-S47A-ki mice) but oppose those characterizing PNPLA3-148M-ki mice (7) . In these mice, very long chain PUFAs are enriched in TGs and depleted in phospholipids. Therefore, the human PNPLA3-148M variant resembles human and mouse PNPLA3 loss of function.
In PNPLA3-148M and PNPLA3-ko cells, PUFA containing DAGs accumulated under lipolytic conditions compared to PNPLA3-148I cells. This was paralleled by a tendency for decreased incorporation of PUFA into PCs in PNPLA3-148M and PNPLA3-ko cells. These data suggest that PNPLA3 promotes transfer of PUFAs from DAGs to generate polyunsaturated PCs, thus refining the model proposed by Mitsche et al. (7) .
It is conceivable that PNPLA3 acts as a PUFA-specific transacylase, catalyzing the transfer of PUFAs in DAGs generated from TG hydrolysis (such as 2,3-DAGs), to yield a PUFA-specific lipase hydrolyzing PUFAs from DAGs, to be used for the synthesis of PUFA-containing PCs. Importantly, the PNPLA3-148M-variant had similar effects to lipid metabolism as PNPLA3 deletion. While we cannot exclude the possibility that I148M substitution results in altered substrate specificity of the enzyme, the data strongly suggest that the I148M substitution results in loss of PNPLA3 activity in human cells. Either way, I148M remodels liver TGs in the human liver in a polyunsaturated direction (22) . This lipid composition opposes the saturated TG composition characterizing liver in NAFLD associated with insulin resistance ('Metabolic NAFLD') (5, 23) . The retention of polyunsaturated TGs in the liver may explain why carriers of the PNPLA3 gene variant are protected against cardiovascular disease despite having an increase in liver fat content (3, 4) .
METHODS
Subjects
A total of 26 subjects who were homozygous for either the C or the G allele at rs738409 and fulfilled the inclusion and exclusion criteria (vide infra) were recruited among nondiabetic individuals who had previously been genotyped for PNPLA3 at rs738409 in our laboratory (24) or in the population-based National FINRISK 2007 (25) . 
Clinical study design
The study consisted of i) a screening visit, ii) a metabolic study visit and iii) a visit to the imaging center for quantification of IHTG using proton magnetic resonance spectroscopy ( 1 H-MRS).
The screening visit was performed after an overnight fast. A history and physical examination were performed to review the inclusion and exclusion criteria. Blood samples were obtained for measurement of circulating blood count, glucose, HbA1c, serum insulin, thyroid stimulating hormone, hepatitis C virus antibody, plasma glucose, low density lipoprotein (LDL)-and high density lipoprotein (HDL)-cholesterol, triglyceride, albumin, thromboplastin time, C-reactive protein, sodium, potassium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT) concentrations as described (24) .
After the screening visit, the subjects wore portable accelerometers (GT3X, Actigraph, Pensacola, FL) for 7 days to estimate their physical activity. The subjects were asked to collect a 3-day dietary record to determine their baseline dietary composition. The dietary records were analyzed using the AivoDiet software (version 2.0.2.3; Aivo Finland, Turku, Finland).
Metabolic study visit. For 3 days prior to the metabolic study day, the subjects were asked to avoid foods naturally enriched in 13 C (such as sea food, corn, and sugar), alcohol, and strenuous exercise. In the previous evening before the metabolic study, the subjects consumed a standardized meal (a vegetarian sandwich, 330 kcal, 21 g fat, 25 g carbohydrate and 9 g protein, produced by Ravioli, Helsinki, Finland). The subjects came to the clinical research center after an overnight fast. Body composition (InBody 720; BioSpace, Seoul, Korea), weight, height and waist circumference were measured as described (5) . A cannula was inserted into an antecubital vein, and baseline blood samples were taken to measure plasma albumin, AST, ALT, ALP, GGT, bilirubin, Cpeptide, glucose, LDL and HDL cholesterol and triglyceride concentrations as well as serum insulin concentrations. Participants were then fed a mixed test meal containing 44 g carbohydrate, 10 g protein and 37 g fat, with 100 mg of [U 13 C]palmitic acid and 100 mg of [U 13 C]linoleic acid (both from Cambridge Isotopes, UK) added to trace the fate of the dietary fatty acids (26) . The meal consisted of 40 g Kellogg's Rice Krispies with 200 g skimmed milk, and a chocolate milkshake containing 20 g butter, 20 g rapeseed oil, sweetener and cocoa powder.
Blood samples were taken at 0, 60, 120, 180, 240, 300, 360, and 420 min after the consumption of the test meal for measurement of plasma glucose, TG, free fatty acids (FFA), and serum insulin concentrations, and at 0, 120, 180, 240, 300, 360 and 420 min for isolation of very-low density lipoprotein (VLDL) and chylomicrons by ultracentrifugation as described (27) . The fatty acid composition and concentrations of 13 C-18:2 and 13 C-16:0 FAs were determined in total plasma, plasma FFA and the VLDL and chylomicron fractions (vide infra). Lipidomics analyses (vide infra) were performed of the VLDL fraction using UHPLC-MS at the time points of 0, 120 and 420 min.
Imaging visit. Before the metabolic study visit, the subjects underwent 1 H-MRS to quantify IHTG content (vide infra).
Isolation of VLDL and chylomicron fractions
Separations of chylomicron of Svedberg flotation rate (Sf) >400 and VLDL-rich fraction (Sf20-400) were made by sequential flotation using density gradient ultracentrifugation (Beckman L-80, Beckman Coulter, Brea, CA) as previously described (23) .
FA isotopic enrichment
To determine the specific FA composition and isotopic enrichment, total lipids were extracted from plasma, and VLDL and chylomicrons and FA methyl esters (FAMEs) prepared (28, 29) . The FA compositions (µmol/100 µmol total FA) of these fractions were determined by gas chromatography (GC), and the fatty acid concentrations calculated (27) . [U- 13 C]palmitate and [U-13 C]linoleate enrichments were measured in plasma FFA, TG, Sf >400 (chylomicron-TG), Sf20-400-TG and VLDL-TG FAMEs derivatives using a Δ Plus XP GC-combustion isotope ratio mass spectrometer (Thermo Electron, Bremen, Germany) (30) . The tracer-to-tracee ratio (TTR) of a baseline measurement before administration of [U-13 C]palmitate was subtracted from the TTR of each sample to account for natural abundance. The TTRs for [U 13 C]palmitate and [U-13 C]linoleate were multiplied by the corresponding unlabeled concentrations to give plasma and lipoprotein tracer concentrations (26) .
Lipidomic analysis of VLDL-TG using UHPLC-MS
The UHPLC-QTOFMS analyses were done in a similar manner than described earlier with some modifications (31) . UHPLC-QTOFMS system was from Agilent 
Measurement of IHTG content by 1 H-MRS
IHTG content was measured by proton magnetic resonance spectroscopy ( 1 H-MRS)
performed on a clinical 1.5T Siemens Avanto fit imager. MRS data was analyzed using jMRUI v5.2 software with AMARES algorithm as described (33) .
Lipidomic analysis of the human liver
We performed re-analysis of TGs and PCs in homozygous carriers (n=7) and noncarriers (n=64) of the PNPLA3 I148M variant in previously described data of human liver lipidome of a separate cohort (5) . Briefly, human liver biopsies were obtained during laparoscopic surgery and immediately frozen in liquid nitrogen. Subsequently, molecular lipids were measured using a Q-TOF Premier (Waters, Milford, MA) quadrupole time-of-flight mass spectrometer combined with an Acquity Ultra Performance LC (Waters, Milford, MA) liquid chromatography as previously described (5) .
Other analyses from human samples
The fasting plasma glucose was measured using the hexokinase method on an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan). Serum 
Lipid analyses from cells
For the determination of unlabeled lipids, cells were extracted and lipids analysed by high-performance thin layer chromatography as in (35) . Click labeling and analyses were performed essentially as described (15, 17) . Briefly, for alkyne-FA labeling, cells grown in 12-well plates were incubated at +37°C, 5% CO2 for 15 min in loading medium containing serum-free DMEM supplemented with 1% fatty acid free BSA, and 
Study approval
The study protocols were approved by the ethics committee of the Hospital District of Helsinki and Uusimaa, Helsinki, Finland. The studies were conducted in accordance with the Declaration of Helsinki. Each participant provided written informed consent after being explained the nature and potential risks of the study.
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